StockData
Matinas BioPharma Holdings, Inc. logo

Matinas BioPharma Holdings, Inc. (MTNB) stock

MTNBNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 0/30
$0.91+0.05 (+6.35%)

Close on Nov 18, 2026Market cap $13.37MP/E –Yield –

Matinas BioPharma operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Matinas BioPharma's operating cash flow for the twelve months ending Jun 30, 2026 was -$6.42M. For fiscal 2025 it was -$7.01M. The highest annual figure on record is -$2.99M in fiscal 2013.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$7.01M–
FY2024Dec 31, 2024-$15.89M–
FY2023Dec 31, 2023-$15.28M–
FY2022Dec 31, 2022-$19.16M–
FY2021Dec 31, 2021-$15.22M–
FY2020Dec 31, 2020-$17.37M–
FY2019Dec 31, 2019-$14.09M–
FY2018Dec 31, 2018-$10.32M–
FY2017Dec 31, 2017-$11.46M–
FY2016Dec 31, 2016-$6.12M–
FY2015Dec 31, 2015-$7.81M–
FY2014Dec 31, 2014-$7.96M–
FY2013Dec 31, 2013-$2.99M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$1.84M–
Q1 FY2026Mar 31, 2026-$1.60M–
Q4 FY2025Dec 31, 2025-$1.51M–
Q3 FY2025Sep 30, 2025-$1.47M–
Q2 FY2025Jun 30, 2025-$2.02M–
Q1 FY2025Mar 31, 2025-$2.01M–
Q4 FY2024Dec 31, 2024-$3.51M–
Q3 FY2024Sep 30, 2024-$3.50M–
Q2 FY2024Jun 30, 2024-$3.11M–
Q1 FY2024Mar 31, 2024-$5.77M–
Q4 FY2023Dec 31, 2023-$4.58M–
Q3 FY2023Sep 30, 2023-$4.42M–
Q2 FY2023Jun 30, 2023-$2.19M–
Q1 FY2023Mar 31, 2023-$4.09M–
Q4 FY2022Dec 31, 2022-$4.30M–
Q3 FY2022Sep 30, 2022-$4.97M–
Q2 FY2022Jun 30, 2022-$5.13M–
Q1 FY2022Mar 31, 2022-$4.76M–
Q4 FY2021Dec 31, 2021-$3.96M–
Q3 FY2021Sep 30, 2021-$5.75M–
Q2 FY2021Jun 30, 2021-$864.66K–
Q1 FY2021Mar 31, 2021-$4.65M–
Q4 FY2020Dec 31, 2020-$4.31M–
Q3 FY2020Sep 30, 2020-$5.23M–
Q2 FY2020Jun 30, 2020-$3.17M–
Q1 FY2020Mar 31, 2020-$4.66M–
Q4 FY2019Dec 31, 2019-$4.90M–
Q3 FY2019Sep 30, 2019-$4.07M–
Q2 FY2019Jun 30, 2019-$2.10M–
Q1 FY2019Mar 31, 2019-$3.02M–
Q4 FY2018Dec 31, 2018-$2.62M–
Q3 FY2018Sep 30, 2018-$2.64M–
Q2 FY2018Jun 30, 2018-$2.26M–
Q1 FY2018Mar 31, 2018-$2.81M–
Q4 FY2017Dec 31, 2017-$1.92M–
Q3 FY2017Sep 30, 2017-$2.78M–
Q2 FY2017Jun 30, 2017-$3.73M–
Q1 FY2017Mar 31, 2017-$3.03M–
Q4 FY2016Dec 31, 2016-$2.12M–
Q3 FY2016Sep 30, 2016-$1.37M–

More Matinas BioPharma figures

See a number that looks wrong?